Enhanced Recovery After Bilateral Reduction Mammaplasty

Sponsor
University of Texas Southwestern Medical Center (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04558840
Collaborator
(none)
100
1
2
31.5
3.2

Study Details

Study Description

Brief Summary

This single-center, clinical trial is being conducted to determine whether non-narcotic pain regiments are as effective as narcotic-based regiments in reducing post-operative pain in patients undergoing breast reduction in the outpatient setting.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Macromastia
N/A

Detailed Description

This is a non-blinded, non-inferiority, randomized control trial with the primary outcome of interest being overall pain, with secondary outcomes including adverse effects from pain medications, patient satisfaction with their pain regiment and with their surgery, and the impact of pain on their daily activities. This study is designed to follow one-hundred (100) qualified and consenting patients seeing the PI/surgeon (JMK) at his office at UT Southwestern for their initial operative consultation for macromastia. If patients meet eligibility criteria, they will be offered enrollment in the trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Enhanced Recovery After Bilateral Reduction Mammaplasty
Actual Study Start Date :
Oct 15, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Enhanced Recovery After Surgery (ERAS) Arm

ERAS Arm will undergo multimodal regiment: Before Surgery- gabepentin 300mg and celecoxib 400mg once the day before surgery and again 3 hours prior to surgery. During surgery- subjects will receive ketorolac 30mg IV ketorolac once (15mg for patients age 64 years and above). Post-operatively- Gabapentin 100mg three times daily for POD0-7, ketorolac 10mg four times daily for POD1-5 days, and ondansetron 4mg as needed for nausea; patients will also have a prescription for hydrocodone-acetaminophen 5/325mg tabs that they may fill if needed for emergency/breakthrough pain.

Procedure: Macromastia
Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
Other Names:
  • Mammaplasty
  • Active Comparator: Current Practice Arm

    The current practice arm will include: post-operatively, hydrocodone-acetaminophen 5/325mg tabs and ibuprofen 800mg, as needed for pain. Additionally, acetaminophen may be used in conjunction with the above regiment. Ibuprofen and acetaminophen can be taken as needed or alternating every 6 hours, scheduled.

    Procedure: Macromastia
    Patients with macromastia seeing the principle investigator (PI) (JMK) at his office at the Outpatient Building, which includes the Outpatient Surgery Center (OSC), in the Department of Plastic Surgery clinic at UT-Southwestern for their initial operative consultation for reduction mammaplasty will be offered enrollment in the trial if they are deemed appropriate surgical candidates, based on the PI's clinical judgement and expertise.
    Other Names:
  • Mammaplasty
  • Outcome Measures

    Primary Outcome Measures

    1. Post-operative Pain Questionnaire [Day 0 - Day 7]

      Determine the efficacy of non-narcotic pain regiments in patients undergoing breast reduction surgery and compare it to narcotic-based pain regiments in improving post-operative pain in patients undergoing breast reduction surgery. Patients will be asked to rate their pain from a scale of 0 ("No Pain") to 10 ("Pain as bad as you can imagine").

    Secondary Outcome Measures

    1. Post operative Patient Satisfaction Questionnaire: Postoperative Reduction Module Satisfaction with Outcome [Day 0- Day 7]

      The following questionnaires will be used to track the patients satisfaction following their procedure: BREAST-Q Postoperative Reduction Module Satisfaction with Outcome. Patients will be asked to rate their satisfaction with: Very dissatisfied, Somewhat dissatisfied, Somewhat satisfied or very satisfied.

    2. Post operative Patient Satisfaction Questionnaire: Postoperative Module Satisfaction with Information Survey [Day 0- Day 7]

      The following questionnaires will be used to track the patients satisfaction following their procedure: BREAST- Q Postoperative Reconstruction Module Satisfaction with Information Survey. Patients will be asked to rate their satisfaction with: Very dissatisfied, Somewhat dissatisfied, Somewhat satisfied or very satisfied.

    3. Post operative Quality of Life Questionnaire [Day 0- Day 7]

      The following questionnaires will be used to track the patients satisfaction following their procedure. The postoperative questions do not have an applicable scale.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • patients undergoing bilateral breast reduction (reduction mammaplasty) with the PI in the outpatient setting

    • Age 18 and older

    • BMI less than 40, non-smokers.

    Exclusion Criteria:
    • age less than 18,

    • BMI over 40,

    • smokers,

    • uncontrolled diabetes,

    • American Society of Anesthesiologists (ASA) status scores 3 or higher

    • patients with allergies to any of the medications in the ERAS or current practice regiments (gabapentin, celecoxib, ketorolac, ondansetron, or hydrocodone).

    • History of narcotic or IV drug abuse

    • History of chronic pain

    • Hypersensitivity or allergy to any of these drugs: gabapentin, celecoxib, ketorolac, hydrocodone, ibuprofen or acetaminophen

    • Current pregnancy or planning pregnancy in the next xx weeks/ months

    • Contraindications to NSAID drugs (ketorolac, ibuprofen, celecoxib): coagulation disorder, active bleeding, severe renal impairment, hepatic impairment.

    • Contraindications to gabapentin: caution for CrCl <60, caution in elderly, caution if alcohol consumption

    • Contraindications to acetaminophen: hepatic or renal impairment, chronic alcohol use

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Texas Southwestern Medical Center Dallas Texas United States 75390

    Sponsors and Collaborators

    • University of Texas Southwestern Medical Center

    Investigators

    • Principal Investigator: Jeffrey Kenkel, UT Southwestern

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jeffrey M. Kenkel, Chairman, Department of Plastic Surgery, University of Texas Southwestern Medical Center
    ClinicalTrials.gov Identifier:
    NCT04558840
    Other Study ID Numbers:
    • STU 2020-0813
    First Posted:
    Sep 22, 2020
    Last Update Posted:
    Jan 28, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes

    Study Results

    No Results Posted as of Jan 28, 2022